Relmada Therapeutics signs exclusive licensing agreement with Trigone Pharma, paying $3.5 million initial fee

Summary

On March 26, Relmada Therapeutics Inc. announced it entered into an exclusive licensing agreement with Trigone Pharma on March 24, as detailed in SEC filings. Relmada will pay Trigone a $3.5 million initial licensing fee. Relmada Therapeutics disclosed the agreement aims to advance NDV-01 for treating non-muscle invasive bladder cancer.rttnews

Impact Analysis

The event is classified at the company level, given it involves Relmada Therapeutics Inc.'s strategic licensing decision. First-order effects include potential revenue generation from NDV-01’s development, enhancing Relmada’s product portfolio and market position in oncology treatments.rttnews Second-order effects may involve increased investor interest, improving stock valuation due to anticipated future revenues and a strengthened competitive profile in the biopharmaceutical industry. Opportunities could arise for investors to consider Relmada Therapeutics as a potential growth stock in the biotech sector, despite current expectations of stable quarterly revenue until the end of 2024.Reuters Risks involve execution challenges in bringing NDV-01 to market and competition within the cancer treatment industry.